PL422982A1 - Universal antigen, universal vaccine against influenza, the system for production of the vaccine, method of production of the antigen and application of the antigen for production of the universal vaccine against influenza - Google Patents

Universal antigen, universal vaccine against influenza, the system for production of the vaccine, method of production of the antigen and application of the antigen for production of the universal vaccine against influenza

Info

Publication number
PL422982A1
PL422982A1 PL422982A PL42298217A PL422982A1 PL 422982 A1 PL422982 A1 PL 422982A1 PL 422982 A PL422982 A PL 422982A PL 42298217 A PL42298217 A PL 42298217A PL 422982 A1 PL422982 A1 PL 422982A1
Authority
PL
Poland
Prior art keywords
antigen
universal
production
vaccine
against influenza
Prior art date
Application number
PL422982A
Other languages
Polish (pl)
Inventor
Edyta Kopera
Bogusław SZEWCZYK
Karolina Uranowska
Original Assignee
Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biochemii I Biofizyki Polskiej Akademii Nauk, Uniwersytet Gdański filed Critical Instytut Biochemii I Biofizyki Polskiej Akademii Nauk
Priority to PL422982A priority Critical patent/PL422982A1/en
Publication of PL422982A1 publication Critical patent/PL422982A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Przedmiotem zgłoszenia są antygen uniwersalny, uniwersalna szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu i zastosowanie antygenu do wytwarzania szczepionki uniwersalnej przeciwko grypie. Rozwiązanie ujęte w zgłoszeniu prowadzi do uzyskania wysoko immunogennego antygenu co nie wymaga kontaktu z wirusem, a jedynie z genem hemaglutyniny. Przedmiotowa szczepionka charakteryzuje się tym, że nie zawiera wirusa ani jego fragmentów, nie zawiera komórek innych organizmów ani ich fragmentów, a jedynie oczyszczony antygen.The subject of the application is a universal antigen, a universal influenza vaccine, a vaccine production system, a method for producing an antigen and the use of an antigen for the preparation of a universal influenza vaccine. The solution included in the application leads to a highly immunogenic antigen which does not require contact with a virus, but only with the hemagglutinin gene. The vaccine is characterized in that it does not contain the virus or its fragments, it does not contain cells of other organisms or their fragments, but only purified antigen.

PL422982A 2017-09-26 2017-09-26 Universal antigen, universal vaccine against influenza, the system for production of the vaccine, method of production of the antigen and application of the antigen for production of the universal vaccine against influenza PL422982A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL422982A PL422982A1 (en) 2017-09-26 2017-09-26 Universal antigen, universal vaccine against influenza, the system for production of the vaccine, method of production of the antigen and application of the antigen for production of the universal vaccine against influenza

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL422982A PL422982A1 (en) 2017-09-26 2017-09-26 Universal antigen, universal vaccine against influenza, the system for production of the vaccine, method of production of the antigen and application of the antigen for production of the universal vaccine against influenza

Publications (1)

Publication Number Publication Date
PL422982A1 true PL422982A1 (en) 2019-04-08

Family

ID=65992048

Family Applications (1)

Application Number Title Priority Date Filing Date
PL422982A PL422982A1 (en) 2017-09-26 2017-09-26 Universal antigen, universal vaccine against influenza, the system for production of the vaccine, method of production of the antigen and application of the antigen for production of the universal vaccine against influenza

Country Status (1)

Country Link
PL (1) PL422982A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015093996A1 (en) * 2013-12-20 2015-06-25 Instytut Biochemii I Biofizyki Pan Antigen, influenza vaccine, system for vaccine manufacturing, method of antigen production, and use of antigen to produce an influenza vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015093996A1 (en) * 2013-12-20 2015-06-25 Instytut Biochemii I Biofizyki Pan Antigen, influenza vaccine, system for vaccine manufacturing, method of antigen production, and use of antigen to produce an influenza vaccine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CREGG J. ET AL., RECOMBINANT PROTEIN EXPRESSION IN PICHIA PASTORIS, 2000 *
STEEL J. ET AL., INFLUENZA VIRUS VACCINE BASED ON THE CONSERVED HEMAGGLUTININ STALK DOMAIN, 2010 *
URANOWSKA K. ET AL., HEMAGGLUTININ STALK DOMAIN FROM H5N1 STRAIN AS A POTENTIALLY UNIVERSAL ANTIGEN (ABSTRACT), 2014 *
URANOWSKA K. ET AL., HEMAGGLUTININ STALK DOMAIN FROM H5N1 STRAIN AS A POTENTIALLY UNIVERSAL ANTIGEN, 2014 *

Similar Documents

Publication Publication Date Title
MX2025003310A (en) Targeted integration of nucleic acids
CL2018000232A1 (en) Peptide mixture (divisional application 201601405)
AR096113A1 (en) F PREFUSION POLYPEPTIDES OF RESPIRATORY AND STABILIZED SYNCHRICAL VIRUSES (RSV)
BR112017008165A2 (en) single domain antibodies directed against intracellular antigens
PH12018500916A1 (en) Antibody neutralizing human respiratory syncytial virus
MX2015013065A (en) Prefusion rsv f proteins and their use.
EA201890527A1 (en) THERAPEUTIC VACCINES AGAINST HPV18
EP4043031A3 (en) Zika viral antigen constructs
PE20160045A1 (en) SOLUBLE AND STABILIZED RESPIRATORY SYNCITIAL VIRUS (RSV) PREFUSION POLYPEPTIDES F
ES2721309T3 (en) Composition for preparing tagatose and method for preparing tagatose from fructose
CL2016002794A1 (en) Peptide vaccine comprising a mutant ras peptide and a chemotherapeutic agent
MX378857B (en) MODIFIED HOST CELLS AND THEIR USES.
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
CY1119957T1 (en) TREATMENT OF PATIENTS WITH THE USE OF ANNOUNCED PHARMACEUTICAL PREPARATION
BR112013020743A2 (en) compositions and methods for influenza therapy and diagnosis
EA201400235A1 (en) VACCINES AGAINST FLU BASED ON H5
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX382530B (en) INACTIVATED CANINE INFLUENZA VACCINES, METHODS FOR PREPARING THEM AND THEIR USES.
MX363149B (en) Influenza nucleoprotein vaccines.
MX2019007924A (en) Influenza vaccines.
EA201792512A1 (en) COMPOSITIONS FOR DELIVERY OF ANTIGENS OF RESPIRATORY SYNTICIAL VIRUS AND NOROVIRUS INTO THE THIN INTESTINE
BR112014020025A8 (en) ROTAVIRUS SUBUNIT VACCINES AND PRODUCTION METHODS AND USE THEREOF
MX2024003337A (en) IMMUNOGENETIC COMPOSITIONS AGAINST INFLUENZA.
MX381745B (en) PESTIVIRUS VACCINES FOR CONGENITAL TREMORS.